Biotech entity

Macrilen

Product

All 1 tracked stories fall under one category: pharma. Macrilen is most often covered alongside Aeterna Zentaris GmbH, which appears in 1 of these 1 story. Macrilen appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 2 original sources each.

Last mentioned: Mar 6, 2026

RSS updates
Share

Entity pulse

Recent coverage · Macrilen

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Macrilen

All 1 tracked stories fall under one category: pharma. Macrilen is most often covered alongside Aeterna Zentaris GmbH, which appears in 1 of these 1 story. Macrilen appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Macrilen. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Strategic Update

    COSCIENS announces cessation of funding for German biopharma subsidiaries.

  2. Wuzhou Agreement

    Distribution deal signed with Wuzhou Drug International Trading Limited.

  3. FDA Type C Meeting

    Regulatory feedback confirms significant hurdles for pediatric expansion.

  4. DETECT Trial Results

    Phase 3 trial for pediatric indication yields disappointing results.

Stories mentioning Macrilen 1

Pharma Neutral

COSCIENS Abandons Biopharma Unit Following Macrilen Pediatric Setback

COSCIENS Biopharma Inc. has announced a definitive strategic shift by ceasing all funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The decision triggers a structured insolvency process for the units following the failure of a Phase 3 pediatric trial for its flagship diagnostic, Macrilen.

2 sources

Macrilen is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.